Vaccination Coverage Among The Adolescent Boys

The study showing that coverage with HPV vaccination; that continuing to increase in boys. Coverage with the human papillomavirus (HPV) vaccine; increasing among boys from 2017 to 2018. Vaccines are recommending for adolescents to prevent diphtheria, pertussis, tetanus, meningococcal disease; and cancers causing by human papillomavirus (HPV).

The researchers found that coverage with at least one dose of HPV vaccine increased from 65.5 to 68.1 % during 2017 to 2018, and the percentage of adolescents up to date with the HPV vaccine series increasing from 48.6 to 51.1%; only boys experiencing these increases. Increasing in vaccination coverage were also seeing for at least one or at least two doses of the meningococcal conjugate vaccine.

Adolescent vaccination coverage in the United States continued to improve for meningococcal; and HPV vaccines and remains high for tetanus; and reduced diphtheria toxoids and acellular pertussis vaccine. Adolescents whose parents reported having received a provider recommendation; were more likely to have received HPV vaccination comparing with adolescents whose parents did not report a provider recommendation.

Coverage with HPV vaccination

Previously identifying disparities in coverage by metropolitan statistical area; and health insurance status persisting. Adolescents whose parents reporting receiving a provider recommendation had higher coverage with at least one dose of the HPV vaccine; the prevalence of parents reporting having receiving a recommendation varying by state from 60 to 91%.

Vaccination coverage increases were also observed for ≥1 MenACWY dose (from 85.1% to 86.6%) and ≥2 MenACWY doses (from 44.3% to 50.8%). Coverage with tetanus and reduced diphtheria toxoids and acellular pertussis vaccine remained stable at 89%. Supporting providers to give recommendations and effectively address parental concerns remains a priority, especially in states and rural areas where provider recommendations were less commonly reported.

History of varicella disease

Coverage for all measures of HPV and MenACWY vaccination and ≥2 varicella vaccine doses among adolescents without a history of varicella disease were lower among adolescents living in non-MSA areas than in those living in MSA principal cities. The largest differences were in HPV up to date status and ≥2-dose MenACWY coverage. Coverage differences between adolescents living in MSA nonprincipal cities and MSA principal cities were observed for HPV vaccination measures and ≥3 hepatitis B doses.

HPV vaccination coverage was higher among adolescents whose parent reporting receiving a provider recommendation. Thus, the provider recommendation continues to be a strong predictor of HPV vaccination. However, even when a provider recommendation was giving, only 75% accepted the vaccine, suggesting that there are other reasons adolescents are not being vaccinating. It is encouraging that HPV vaccination coverage among boys continues to increase; however, the lack of an increase among girls is concerning.